Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

Yang L, Rieves D, Ganley C.

N Engl J Med. 2012 Sep 6;367(10):885-7. doi: 10.1056/NEJMp1208061. No abstract available.

2.

Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.

Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, Zamora J, Jiménez-Huete A, Haberkamp M, Pohly J, Enzmann H, Zinserling J, Strassmann V, Broich K.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S395-9. doi: 10.1016/j.jalz.2013.09.007. Epub 2014 Jan 10.

PMID:
24418060
3.

Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2013 Feb;27(5):1-4. No abstract available.

PMID:
23589929
4.

Radioactive agent approved as part of Alzheimer disease workup.

Thompson CA.

Am J Health Syst Pharm. 2012 May 15;69(10):818. doi: 10.2146/news120033. No abstract available.

PMID:
22555074
5.

An imaging agent for amyloid.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5. No abstract available.

PMID:
22777304
6.

Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.

Klunk WE.

Arch Neurol. 2008 Oct;65(10):1281-3. doi: 10.1001/archneur.65.10.1281. No abstract available.

7.

Florbetapir F 18 for brain imaging of β-amyloid plaques.

Romano M, Buratti E.

Drugs Today (Barc). 2013 Mar;49(3):181-93. doi: 10.1358/dot.2013.49.3.1937428.

PMID:
23527322
8.

Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.

Beach TG, Schneider JA, Sue LI, Serrano G, Dugger BN, Monsell SE, Kukull W.

J Neuropathol Exp Neurol. 2014 Oct;73(10):948-53. doi: 10.1097/NEN.0000000000000114.

9.

Florbetapir-PET imaging and postmortem beta-amyloid pathology.

Carome M, Wolfe S.

JAMA. 2011 May 11;305(18):1857; author reply 1857-8. doi: 10.1001/jama.2011.579. No abstract available.

PMID:
21558513
10.

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, Clark CM.

Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):8-16. doi: 10.1097/WAD.0b013e31821300bc.

11.

FDA approves 18F-florbetapir PET agent.

[No authors listed]

J Nucl Med. 2012 Jun;53(6):15N. No abstract available.

12.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.

13.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.

Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11.

PMID:
21747008
14.

Amyloid imaging: liberal or conservative? Let the data decide.

Jagust WJ.

Arch Neurol. 2011 Nov;68(11):1377-8. doi: 10.1001/archneurol.2011.152. Epub 2011 Jul 11. No abstract available.

PMID:
21747005
15.
16.

Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.

Zannas AS, Doraiswamy PM, Shpanskaya KS, Murphy KR, Petrella JR, Burke JR, Wong TZ.

Neurocase. 2014 Aug;20(4):466-73. doi: 10.1080/13554794.2013.791867. Epub 2013 May 14.

PMID:
23672654
17.

Use of florbetapir-PET for imaging beta-amyloid pathology.

Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM; AV45-A07 Study Group.

JAMA. 2011 Jan 19;305(3):275-83. doi: 10.1001/jama.2010.2008. Erratum in: JAMA. 2011 Mar 16;305(11):1096. Reiman, P Eric M [corrected to Reiman, Eric M].

PMID:
21245183
18.

[Amyloid PET imaging with [18F]AV-45].

Tateno A, Okubo Y.

Nihon Rinsho. 2011 Oct;69 Suppl 8:561-4. Japanese. No abstract available.

PMID:
22787851
19.

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.

Arch Neurol. 2009 Jan;66(1):60-7. doi: 10.1001/archneurol.2008.511.

20.

Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.

Wey SP, Weng CC, Lin KJ, Yao CH, Yen TC, Kung HF, Skovronsky D, Kung MP.

Nucl Med Biol. 2009 May;36(4):411-7. doi: 10.1016/j.nucmedbio.2009.01.013. Epub 2009 Mar 26.

PMID:
19423009

Supplemental Content

Support Center